News & Updates
Filter by Specialty:
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
03 Aug 2023
COVID-19 vaccines may elicit cross-reactive T-cell responses for long-term protection
Researchers from the Chinese University of Hong Kong (CUHK) have reported that two doses of either mRNA-based BNT162b2 or inactivated CZ02 vaccine elicit cross-reactive T-cell responses. Identification of vaccine-induced memory T cells indicates potential long-term protection with COVID-19 vaccines.
COVID-19 vaccines may elicit cross-reactive T-cell responses for long-term protection
01 Aug 2023
Minimal monitoring feasible in HCV patients on SOF/VEL
Minimal monitoring is feasible in patients with active hepatitis C virus (HCV) infection treated with sofosbuvir/velpatasvir (SOF/VEL), with high rates of sustained virologic response (SVR) reported, including in patients with novel HCV subtypes, according to new data from the phase IV MINMON study presented at IDDF 2023.
Minimal monitoring feasible in HCV patients on SOF/VEL
26 Jul 2023
SG data: Booster mRNA vax shots shield cancer-affected individuals from COVID-19
Administration of booster doses of mRNA-based vaccines provide protection against COVID-19 and its adverse outcomes in patients with cancer who are actively receiving treatment as well as in cancer survivors, as shown in a study from Singapore.